Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Advancements in Alzheimer’s Disease Therapeutics and Biomarkers

July 31, 2025

At the 2025 Alzheimer's Association International Conference, NewAmsterdam Pharma presented data from the Broadway trial highlighting its cholesterol-lowering drug obicetrapib's ability to reduce...

Frazier Life Sciences Secures $1.3B for Early-Stage Biotech Investments

July 31, 2025

Frazier Life Sciences announced the successful closure of its twelfth venture fund at $1.3 billion, earmarked for early-stage biotechnology startups. The oversubscribed fund boosts its capital...

Medicare Coverage Expansion Boosts Molecular Residual Disease Testing

July 31, 2025

Saga Diagnostics' Pathlight molecular residual disease (MRD) assay received positive Medicare reimbursement coverage through the MolDx program, allowing surveillance in stage II-III breast cancer...

Breakthroughs in AI-Driven Gene Editing and Artificial Intelligence in Biotech

July 31, 2025

Cutting-edge AI tools are accelerating the design and application of gene editing technologies. Profluent's OpenCRISPR-1, an AI-generated programmable gene editor, demonstrates superior editing...

Regulatory and Commercial Developments in Pharma and Biotech

July 31, 2025

The sector witnesses significant commercial realignments and strategic partnerships. Madrigal Pharmaceuticals struck a $2 billion exclusive global license for CSPC Pharmaceutical's preclinical...

Metabolic Surgery and Obesity-Diabetes Mechanisms Uncovered

July 31, 2025

Metabolic surgery stands among the most effective treatments for obesity and type 2 diabetes, yet its biological mechanisms remain incompletely understood. A recent comprehensive review published...

Novel Diagnostic and Therapeutic Innovations in Ophthalmology

July 31, 2025

Recent regulatory approvals and clinical advancements are shaping ophthalmic care. Lenz Therapeutics received FDA clearance to launch aceclidine-based eye drops addressing presbyopia, entering a...

Frazier Life Sciences Raises $1.3 Billion for Early-Stage Biotech Investments

July 31, 2025

Frazier Life Sciences has closed an oversubscribed $1.3 billion venture capital fund to support the creation and early-stage development of innovative biopharmaceutical companies. This marks the...

FDA Leadership Shakeup: Vinay Prasad's Departure Sparks Industry Reactions

July 31, 2025

Vinay Prasad has abruptly left his role as head of the FDA's Center for Biologics Evaluation and Research following controversial regulatory decisions including halting Sarepta Therapeutics’...

Eli Lilly’s Mounjaro Shows Cardiovascular Safety in Major Diabetes Trial

July 31, 2025

Eli Lilly’s diabetes drug Mounjaro matched the cardiovascular safety profile of the company's older drug Trulicity in a large cardiovascular outcomes trial involving type 2 diabetes patients....

Respiratory Viral Infections Reactivate Dormant Breast Cancer Cells in Lungs

July 31, 2025

A multidisciplinary research team has uncovered direct evidence that common respiratory viruses—such as influenza and SARS-CoV-2—can reactivate dormant metastatic breast cancer cells in the lungs....

Madrigal Pharmaceuticals Secures $120M for Preclinical GLP-1 Agonist from CSPC

July 31, 2025

Madrigal Pharmaceuticals has entered an exclusive global licensing agreement with CSPC Pharmaceutical Group for SYH-2086, a preclinical oral small-molecule glucagon-like peptide-1 (GLP-1) receptor...

Saga Diagnostics Gains Medicare Coverage for Breast Cancer Recurrence Test

July 31, 2025

Saga Diagnostics’ Pathlight molecular residual disease (MRD) test has received positive Medicare coverage through the MolDx program for surveillance monitoring of breast cancer recurrence across...

Nautilus Biotechnology Focuses on Targeted Proteomics Amid Platform Development

July 31, 2025

Nautilus Biotechnology reported Q2 2025 financial results and highlighted progress in developing its proteome-scale single-molecule proteomics platform, targeting a 2026 launch. The company...

Novavax Reports Development of Vaccine Candidate Against Avian Influenza

July 31, 2025

Novavax has announced progress on a vaccine candidate targeting the avian influenza A(H5N1) virus, clade 2.3.4.4b. The vaccine aims to address pandemic threats arising from bird-to-human and...

Gene Therapy at Birth Shows Durable Protection Against HIV in Primates

July 31, 2025

A pioneering gene therapy study using adeno-associated virus (AAV) vectors demonstrated that a single injection of broadly neutralizing antibody (bNAb) genes delivered at birth can provide...

New AI System Automates Design and Analysis of CRISPR Gene Editing

July 31, 2025

Researchers from Stanford, Princeton, Google DeepMind, and UC Berkeley have developed CRISPR-GPT, an AI-driven agentic system that automates the design and analysis of CRISPR gene-editing...

FDA Leadership Shakeup Rocks Biotech Stocks

July 31, 2025

Vinay Prasad abruptly resigned as director of the FDA's Center for Biologics Evaluation and Research (CBER) amid controversy surrounding gene therapy approvals and policy disputes. His tenure saw...

Alnylam’s Amvuttra Sales Surge Post-Label Expansion

July 31, 2025

Alnylam Pharmaceuticals raised its 2025 revenue forecast after its drug Amvuttra, used for treating hereditary transthyretin amyloidosis, saw rapid sales growth following a label expansion....

Madrigal Secures CSPC’s GLP-1 Agonist with $2B Deal

July 31, 2025

Madrigal Pharmaceuticals inked an exclusive global licensing agreement worth over $2 billion to develop CSPC Pharmaceutical’s preclinical oral GLP-1 receptor agonist SYH-2086. The partnership aims...